CA19-9 as a Serum Marker for Poor Prognosis in Urothelial Carcinoma

Publisher： Karger

E-ISSN： 1423-0399|72|2|112-117

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.72, Iss.2, 2004-02, pp. : 112-117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CA19-9 as a Serum Marker for Poor Prognosis in Urothelial Carcinoma

By  

Urologia Internationalis, Vol. 73, Iss. 4, 2004-12 ,pp. : 357-357

Karger

Access to resources Recommend Favorite

Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy?

By  

Oncology Research and Treatment, Vol. 30, Iss. 1-2, 2007-01 ,pp. : 39-42

Karger

Access to resources Recommend Favorite

Marked Elevation of Serum CA19-9 and Stomach Carcinoma

By  

Oncology, Vol. 55, Iss. 5, 1998-08 ,pp. : 487-488

Karger

Access to resources Recommend Favorite

Clinical Usefulness of CEA, CA19-9, and CYFRA 21-1 as Tumor Markers for Urothelial Bladder Carcinoma

By  

Urologia Internationalis, Vol. 87, Iss. 4, 2011-10 ,pp. : 420-428

Karger

Access to resources Recommend Favorite

Urinary bladder urothelial carcinoma with concurrent plasmacytoid and micropapillary differentiations: A report of two cases with an emphasis on serum carbohydrate antigen 19‐9

By  

PATHOLOGY INTERNATIONAL, Vol. 65, Iss. 9, 2015-09 ,pp. : 495-500

John Wiley & Sons Inc

Access to resources Recommend Favorite